怡肾丸治疗慢性肾衰竭（CKD2~4期）临床回顾性研究∗

摘要

目的：：通过怡肾丸对慢性肾衰竭( CKD2~4期)临床治疗的回顾性研究，评价怡肾丸治疗慢性肾衰竭( CKD 2~4期)的临床疗效与安全性。方法：以2012年6月~2014年3月间，湖南中医药大学第一附属医院肾内科住院及门诊接受怡肾丸治疗的慢性肾衰竭( CKD2~4期)患者为研究对象，分别观察怡肾丸组与对照组治疗慢性肾衰竭( CKD2~4期)临床疗效、中医证候指标及安全性。结果：两组中医证候疗效、中医证候积分、西医疗效评定、肾功能及血红蛋白的影响比较中均较治疗前改善，且差异有统计学意义(P<0.05)；在治疗后分别组间比较中，发现怡肾丸组在中医证候疗效、中医证候积分、西医疗效、肾功能及血红蛋白的影响中优于对照组，且差异有统计学意义(P<0.05)，同时未发现不良反应。结论：怡肾丸可有效延缓慢性肾衰竭( CKD3~4期)进展，同时可改善患者临床症状，提高患者生活质量，且具有一定安全性。%Objective:Through the Yishen pills for chronic renal failure (CKD2~4) clinical retrospective study, evaluation of Yishen pills for the treatment of chronic renal failure ( CKD2 ~4 ) clinical efficacy and safety. Methods:In June 2012 ~March 2014, the First Affiliated Hospital of Hunan University of TCM Renal medical inpatient and outpatient accept Yishen pill treatment of patients with chronic renal failure (CKD2~4) as the research object, respectively to observe Yishen pill group and control group in the treatment of chronic renal failure (CKD2~4) clinical efficacy, TCM syndrome indicators, and security. Results:Two groups of TCM syndrome efficacy, TCM syndrome integral, western medicine curative effect evaluation, the influence of hemoglobin and renal function comparison was improved, the and the difference was statist ically significant (P<0. 05); After treatment, respectively, comparisons between groups, found Yishen pill group in TCM syndrome efficacy, TCM syndrome integral, western medicine curative effect, the impact of renal function and hemoglobin is better than that of control group, and the difference was statistically significant (P<0. 05), and found no adverse reactions. Conclusion:Yishen pill can effectively delay the chronic renal failure (CKD3~4), at the same time can improve clinical symptoms, improve patient quality of life, and has a certain security.